Categories

Entrada publicada a:

Monday September 08th, 2014

The Clínic-UB Campus of the Josep Carreras Research Institute has been inaugurated

Last September 5th, the Aula Magna of the Faculty of Medicine of the University of Barcelona hosted the opening ceremony of the laboratories and facilities of the Clinic-UB Campus of the Josep Carreras Leukaemia Research Institute with the aim of achieving that leukaemia become, one day, 100% curable.

Mr. Xavier Trias, mayor of Barcelona, Mr. Antoni Castellà, Secretary General of Universities and Research of the Catalan Government; Dr. Carles Constante, Director of Planning and Health Research of the Catalan Government; Dr. Dídac Ramírez, Rector of the University of Barcelona (UB) and Mr. Josep Carreras, president of the José Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute Foundation (IJC) have lead the ceremony visiting the new laboratories, scientifically led by Dr. Pablo Menéndez and coordinated by Dr. Alvaro Urbano-Ispizua.

Dr. Josep M. Piqué, General Director of the Hospital Clínic, Dr. Francesc Cardellach, Dean of the Faculty of Medicine of the UB, and Dr. Ciril Rozman have also participated in this inaugural event which means increasing existing scientific references in the field of study of leukaemia and other haematological malignancies, diseases that affect thousands of people every year in Spain.

The activity of first importance of the Josep Carreras Leukaemia Research Institute at these Campus located in UB, is focused on the development of basic, translational and clinical research projects in the field of study of the (normal and leukemic) haematopoietic stem cells, and cell therapy, which corresponds to two lines of current research priority of the IJC. Research in hematopoietic progenitors and cell therapy, is performed in the framework of Cell Therapy UB (TCUB) coordinated by the Faculty of Medicine, which includes preclinical and clinical research teams of various medical specialties. Also, different projects are being developed on clinical and translational research in certain diseases such as acute myeloblastic leukaemia, myelodysplastic syndromes, and multiple myeloma.

The Clinic-UB Campus of the Josep Carreras Leukaemia Research Institute has a molecular lab, a Laboratory of Flow Cytometry, a Cryobiology room and the IJC has contributed to the development of the animal facility. Similarly, due to the complexity of some processes, the IJC has remodelled some shared facilities of the UB in the areas of microscopy, proteomics and genomics to ensure their optimal use.

Currently at the Clinic-UB Campus different teams are conducting the following investigations:

•    Leukaemia Stem Cell Group. Study of the leukaemia stem cell.

•    Stem cells, mesenchymal cancer and development. Study of human pluripotent and multipotent stem cells.

•    Stem Cell Transplantation. Cell therapy for the prevention and treatment of major complications of hematopoietic transplantation.

•    Barcelona Endothelium Team (BET). Study of the role of endothelial dysfunction in various diseases and complications due to transplants.

•    Acute myeloblastic leukaemia. Study of the molecular prognostic factors and new therapeutic targets for the treatment of AML.

•    Monoclonal gammopathies. Study of predictive factors and clinical trials phase I, II and III for the treatment of multiple myeloma with new molecules.

More information at Josep Carreras Leukaemia Research Institute.

Share or bookmark this post

  • Delicious
  • Facebook
  • Twitter
  • email
  • LinkedIn
  • StumbleUpon

    Comments are closed.